Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab Open-Label Extension in heFH
NCT01576484Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2012
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Regeneron Pharmaceuticals. Started Feb 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT01576484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01576484.